Researchers at Boston University Chobanian & Avedisian School of Medicine have built an artificial intelligence (AI) tool ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Growing research shows common herpes viruses may raise dementia risk, challenging previous skepticism and opening new paths ...

Besides delving more deeply into the PET-derived plaque measurements -- showing favorable effects in key brain regions, for example -- Klein also reported on amyloid-beta and tau protein ...

In Alzheimer's disease, proteins like amyloid beta form clumps, known as plaques, that damage the brain.

There are two major proteins that have been associated with the disease, and recent years have seen something of a push-and-pull between scientists trying to determine which of the two, amyloid-β or ...

- Voyager’s wholly-owned Alzheimer’s disease franchise now includes clinical-stage anti-tau antibody VY7523 as well as gene therapies targeting tau, amyloid, and APOE - ...

A recent study of patients who developed bipolar disorder or depression later in life revealed that half had high concentrations of dementia-causing proteins in their brains.

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...

FDA approves expanded indications for GE HealthCare's Vizamyl PET imaging agent for beta amyloid detection, enabling more precise care for Alzheimer's ...

By analyzing thousands of Aβ42 peptides, the scientists gained a better understanding of how mutations in Aβ affect protein aggregation.